25 results on '"Vinorelbine"'
Search Results
2. Mitomycin / Vinorelbine in der Therapie des fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoms bei chemotherapeutisch vorbehandelten Patienten
- Author
-
Godde, Felix Johannes
- Subjects
Lung neoplasms ,Mitomycin ,Vinorelbine ,ddc:610 ,Drug therapy ,Carcinoma, non-small-cell lung ,DDC 610 / Medicine & health ,Second-line therapy - Abstract
Single-agent therapy with Docetaxel or Pemetrexed is the current therapy of choice for second-line treatment in advanced non.small.cell lung cancer (NSCLC). The role of older agents was underattended over the last years. This study presents the combination of Mitomycin C and vinorelbine in pretreated patients. Forty-two patients (stage IIIB and IV, pretreated with platinum-based chemotherapy) received 8 mg m-2 Mitomycin C on day 1 and 25 mg m-2 Vinorelbine on day 1 and 8 of a 28-day cycle. End points were objective tumor response, survival and toxicity. Additionally, QoL was assessed. Five patients (11.9 %) achieved partial responses and 13 patients (31.9 %) stable disease. Progression-free survival was 16 weeks. The median overall survival was 8.5 months. Eleven patients (26.2 %) suffered from grade 3 or 4 neutropenia and four patients (9.5 %) from grade 3 or 4 anaemia. Evaluation of QoL showed that some items amelirated during therapy. The therapeutic concept including Mitomycin C and vinorelbine offers an efficacious and well tolerated regimen with relatively low toxicity. Objective response and survival data correlate with other second-line studies using different medication. As costs of Mitomycin C and vinorelbine are lower compared with current drugs of choice, this regimen is likely to be cost-saving.
- Published
- 2012
3. [Antineoplastic drug-induced extravasation]
- Author
-
Maike, de Wit
- Subjects
Male ,Wound Healing ,Lung Neoplasms ,Brain Neoplasms ,Injections, Subcutaneous ,Hyaluronoglucosaminidase ,Pharyngeal Neoplasms ,Vinorelbine ,Middle Aged ,Vinblastine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Cisplatin ,Deglutition Disorders ,Infusions, Intravenous ,Extravasation of Diagnostic and Therapeutic Materials - Published
- 2010
4. [Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors]
- Author
-
H-J, Raatschen, Y, Fu, V, Rogut, G H, Simon, B, Sennino, K-J, Wolf, and R C, Brasch
- Subjects
Gadolinium DTPA ,Metabolic Clearance Rate ,Melanoma, Experimental ,Contrast Media ,Angiogenesis Inhibitors ,Antibodies, Monoclonal, Humanized ,Vinblastine ,Capillary Permeability ,Rats, Nude ,Albumins ,Cell Line, Tumor ,Image Processing, Computer-Assisted ,Animals ,Humans ,Infusions, Intravenous ,Dose-Response Relationship, Drug ,Microcirculation ,Antibodies, Monoclonal ,Vinorelbine ,Image Enhancement ,Antineoplastic Agents, Phytogenic ,Magnetic Resonance Imaging ,Xenograft Model Antitumor Assays ,Rats ,Bevacizumab ,Female - Abstract
To determine the effects of MRI-assayed vascular leakiness on the delivery of macromolecular therapeutics to tumors.MDA-MB 435 tumors, subcutaneously implanted into nude rats were treated with a single dose of bevacizumab at levels of 0.1 mg (n = 5) or 1.0 mg (n = 10) or received saline (control animals, n = 8). After 24 hours, albumin-(Gd-DTPA) (30)-enhanced MRI was performed. Just prior to MRI, the cytotoxic drug vinorelbine was administered intravenously. Upon completion of the MR experiment, tumor vinorelbine concentrations were quantified by high performance liquid chromatography (HPLC). Vascular leakiness (K (PS)) was calculated based on the MRI data using a pharmacokinetic model.K (PS) was calculated as 3.70 +/- 1.12 (control tumors), 1.95 +/- 0.70 (0.1 mg group) and 0.75 +/- 0.46 microl min (-1)cm (-3) (1.0 mg group). K (PS) was significantly higher in the control group compared to the 1.0 mg bevacizumab group. Vinorelbine concentrations were measured as 409.4 +/- 109.7 (control tumors), 387.5 +/- 47.5 (0.1 mg group) and 250.7 +/- 71.9 (1.0 mg group). These differences were not significant. A moderate and significant correlation was found between K (PS) and Vinorelbine concentrations in tumors (r = 0.49, p0.05).MRI-assayed K (PS) based on dynamic MRI enhanced by albumin-(Gd-DTPA) (30) correlated significantly with vinorelbine accumulation in experimental xenograft tumors under angiogenesis inhibition. Thus, the MRI technique applied in our study could potentially help to predict accumulation of macromolecular cytotoxic drugs and to optimize individual therapeutic regimes in tumors.
- Published
- 2009
5. [Atypical case of bronchus carcinoma]
- Author
-
B, Chatterjee, D, Berger, Ch, Joost, and A, Stucki
- Subjects
Male ,Lung Neoplasms ,Brain Neoplasms ,Polyuria ,Antidiuretic Agents ,Palliative Care ,Antineoplastic Agents ,Radiotherapy Dosage ,Vinorelbine ,Middle Aged ,Vinblastine ,Antineoplastic Agents, Phytogenic ,Carboplatin ,Diagnosis, Differential ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Deamino Arginine Vasopressin ,Radiography, Thoracic ,Neoplasm Metastasis ,Lung ,Diabetes Insipidus - Abstract
Bronchuscarcinoma ist the most frequent death cause with tumor patients. At time of diagnosis the stadium is often already advanced, the patient is inoperable. We present a patient (non-smoker) with polydipsia, visual troubles and polyuria. The lab results confirmed diabetes insipidus, but the following x-rays proved multiple intracerebral spots. And also multiple spots in the lungs, the mediastinum, in the liver, the coloumn and the adrenals. Histological diagnosis was non small cell lung cancer (NSCLC).
- Published
- 2008
6. [Palliative chemotherapy of head and neck cancer: present status and future development]
- Author
-
B, Hennemann
- Subjects
Antimetabolites, Antineoplastic ,Time Factors ,Antineoplastic Agents ,Vinblastine ,Deoxycytidine ,Clinical Trials, Phase II as Topic ,Antineoplastic Combined Chemotherapy Protocols ,Animals ,Humans ,Neoplasm Metastasis ,Protein Kinase Inhibitors ,Clinical Trials as Topic ,Patient Selection ,Palliative Care ,Gefitinib ,Vinorelbine ,Protein-Tyrosine Kinases ,Antineoplastic Agents, Phytogenic ,Gemcitabine ,Rats ,ErbB Receptors ,Treatment Outcome ,Clinical Trials, Phase III as Topic ,Head and Neck Neoplasms ,Disease Progression ,Quinazolines ,Taxoids ,Cisplatin ,Neoplasm Recurrence, Local ,Forecasting - Abstract
Patients with head and neck tumors are treated with palliative chemotherapy in case of the detection of distant metastases or local recurrence without the option of surgical therapy or radiation. Alongside 5-fluorouracil (5-FU) in combination with cisplatin or carboplatin, taxanes, gemcitabine and vinorelbine as well as monoclonal antibodies or small molecule tyrosine kinase inhibitors have been used.This review analyses the published literature of the past 15 years, including selected abstracts with view to response rate, overall survival and adverse effects.5-FU plus cisplatin or carboplatin can still be considered as standard treatment, achieving response rates of 20-30 %. The addition of taxanes increases the objective response rate but adds remarkable toxicity to the treatment protocol. Phase III studies demonstrate higher response rates but fail to demonstrate a significant increase of the overall survival after polychemotherapy as compared to monotherapy protocols. Thus, patients with a reduced performance can be treated with monotherapy. In case of disease progression after cisplatin-containing chemotherapy further treatment should only be offered to selected patients. For this situation, platin-free chemotherapy protocols containing taxanes, gemcitabine or vinorelbine seem promising. Recent studies with monoclonal antibodies or small molecule tyrosine kinase inhibitors report on a response rate of 10-20 %.The use of new drugs increases the response rate and amends the side effects of the chemotherapy. However, phase III studies documenting an improved overall survival are lacking. Targeted therapies broaden the therapeutic armament, and possibly, EGFR inhibition will help to overcome chemotherapy resistance in the future.
- Published
- 2006
7. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma]
- Author
-
Volker, Bartsch
- Subjects
Clinical Trials as Topic ,Lung Neoplasms ,Dose-Response Relationship, Drug ,Administration, Oral ,Biological Availability ,Breast Neoplasms ,Vinorelbine ,Vinblastine ,Antineoplastic Agents, Phytogenic ,Drug Administration Schedule ,Survival Rate ,Treatment Outcome ,Chemotherapy, Adjuvant ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Infusions, Intravenous ,Neoplasm Staging - Abstract
The development of an oral formulation of vinorelbine (Navelbine softgelatine capsules, Pierre Fabre Pharma, Freiburg i.Br., Germany) represents a significant advance in the treatment of patients with cancer. Oral chemotherapy is more convenient for the patients and brings significant time savings. Vinorelbine is rapidly absorbed after oral ingestion. The bioavailability is in the range of 33 to 43% and is not affected by concomitant food intake or by vomiting occuring 1.5 h or later after dosing. No significant differences in the pharmacokinetics of oral vinorelbine were observed between elderly (or =70 years) and younger patients. The recommended dose schedule for oral vinorelbine is 60 mg/m(2) weekly for the initial 3 weeks (cycle 1) and 80 mg/m(2) weekly thereafter. However, if severe neutropenia is encountered during the first cycle, treatment is continued with weekly doses of 60 mg/m(2). Bioavailability studies have demonstrated that oral vinorelbine doses of 60 and 80 mg/m(2) are comparable to intravenous doses of 25 and 30 mg/m(2), respectively. Several clinical studies have demonstrated that the new oral formulation of vinorelbine can be safely administered, even to elderly patients, and is comparable in activity to intravenous vinorelbine in advanced non-small cell lung cancer (NSCLC) and metastatic breast cancer (MBC). A randomized phase II comparison of oral vinorelbine at the recommended dose schedule vs. intravenous vinorelbine at 30 mg/(2) in patients with advanced NSCLC found no significant differences in response rate, progression-free and overall survival between the two treatments. In studies of combination chemotherapy using vinorelbine plus cisplatin or carboplatin in advanced NSCLC, or vinorelbine plus taxanes, capecitabine,epirubicin, or the monoclonal HER2/neu antibody trastuzumab in MBC, intravenous vinorelbine could be completely or partially replaced by oral vinorelbine, resulting in maintained efficacy, good tolerability and improved patient convenience. Concurrent chemoradiation with oral vinorelbine and cisplatin was shown to be well tolerated and produced significant down-staging in patients with locally advanced NSCLC. Metronomic chemotherapy is a new treatment approach designed to maximize the antiangiogenic effect. Oral vinorelbine given every other day at low doses is currently evaluated in patients with refractory solid tumors. Oral vinorelbine has also proven useful as a substitute for intravenous vinorelbine in patients experiencing intractable acute tumor pain during or after intravenous infusion of vinorelbine.
- Published
- 2006
8. [Vinorelbine in patients with malignant pleural mesothelioma--a phase II study]
- Author
-
E, Ost and H J, Illiger
- Subjects
Mesothelioma ,Treatment Outcome ,Pleural Neoplasms ,Quality of Life ,Humans ,Vinorelbine ,Vinblastine ,Drug Administration Schedule ,Follow-Up Studies ,Neoplasm Staging - Published
- 2001
9. [Adverse (cardio-)vascular effects of vinorelbine in non-small-cell bronchial carcinoma]
- Author
-
J, Kirschner, M, Kolb, J, Müller, and I, Jacobi
- Subjects
Male ,Lung Neoplasms ,Myocardial Infarction ,Vinorelbine ,Middle Aged ,Vinblastine ,Antineoplastic Agents, Phytogenic ,Angina Pectoris ,Electrocardiography ,Risk Factors ,Carcinoma, Non-Small-Cell Lung ,Hypertension ,Humans ,Aged - Abstract
Vinorelbin is an important tumouricidal substance. The (cardio-)vascular side effects are not well known. We report on four patients in highly palliative situations who were treated with vinorelbine for non-small cell lung cancer. Case one presented with myocardial infarction eleven days after onset of therapy. The second and third cases had to be admitted immediately after the beginning of vinorelbine treatment because of hypertension and angina pectoris. The fourth case suffered from angina abdominalis. A critical review of the literature showed 17 cardiac ischaemias with seven myocardial infarctions, three of them with lethal outcome.
- Published
- 2000
10. [New cytostatics in the therapy of non-small cell bronchial carcinoma]
- Author
-
M, Serke, N, Schönfeld, and R, Loddenkemper
- Subjects
Bridged-Ring Compounds ,Antimetabolites, Antineoplastic ,Lung Neoplasms ,Paclitaxel ,Bronchial Neoplasms ,Vinorelbine ,Vinblastine ,Antineoplastic Agents, Phytogenic ,Deoxycytidine ,Gemcitabine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Taxoids - Published
- 1998
11. [Phlebitis after vinorelbine]
- Author
-
C, Sauter, A, Margulies, and B, Pestalozzi
- Subjects
Neoplasms ,Humans ,Vinorelbine ,Infusions, Intravenous ,Phlebitis ,Vinblastine ,Antineoplastic Agents, Phytogenic - Published
- 1998
12. Therapie des nicht-resektablen malignen Pleuramesothelioms.
- Author
-
Serke, Monika
- Abstract
Copyright of DoctorConsult - The Journal. Wissen fur Klinik und Praxis is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2011
- Full Text
- View/download PDF
13. [Antineoplastic drug-induced extravasation].
- Author
-
de Wit M
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms radiotherapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Cisplatin administration & dosage, Cisplatin adverse effects, Deglutition Disorders drug therapy, Deglutition Disorders radiotherapy, Humans, Hyaluronoglucosaminidase administration & dosage, Infusions, Intravenous, Injections, Subcutaneous, Lung Neoplasms radiotherapy, Male, Middle Aged, Pharyngeal Neoplasms radiotherapy, Vinblastine administration & dosage, Vinblastine adverse effects, Vinblastine analogs & derivatives, Vinorelbine, Wound Healing drug effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Brain Neoplasms drug therapy, Brain Neoplasms secondary, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung secondary, Extravasation of Diagnostic and Therapeutic Materials drug therapy, Extravasation of Diagnostic and Therapeutic Materials etiology, Lung Neoplasms drug therapy, Pharyngeal Neoplasms drug therapy, Pharyngeal Neoplasms secondary
- Published
- 2010
- Full Text
- View/download PDF
14. [Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors].
- Author
-
Raatschen HJ, Fu Y, Rogut V, Simon GH, Sennino B, Wolf KJ, and Brasch RC
- Subjects
- Albumins pharmacokinetics, Angiogenesis Inhibitors pharmacology, Animals, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized, Bevacizumab, Cell Line, Tumor, Contrast Media pharmacokinetics, Dose-Response Relationship, Drug, Female, Gadolinium DTPA pharmacokinetics, Humans, Infusions, Intravenous, Melanoma, Experimental drug therapy, Metabolic Clearance Rate physiology, Microcirculation physiology, Rats, Rats, Nude, Vinblastine pharmacokinetics, Vinorelbine, Antineoplastic Agents, Phytogenic pharmacokinetics, Capillary Permeability physiology, Image Enhancement, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Melanoma, Experimental blood supply, Melanoma, Experimental metabolism, Vinblastine analogs & derivatives, Xenograft Model Antitumor Assays
- Abstract
Purpose: To determine the effects of MRI-assayed vascular leakiness on the delivery of macromolecular therapeutics to tumors., Materials and Methods: MDA-MB 435 tumors, subcutaneously implanted into nude rats were treated with a single dose of bevacizumab at levels of 0.1 mg (n = 5) or 1.0 mg (n = 10) or received saline (control animals, n = 8). After 24 hours, albumin-(Gd-DTPA) (30)-enhanced MRI was performed. Just prior to MRI, the cytotoxic drug vinorelbine was administered intravenously. Upon completion of the MR experiment, tumor vinorelbine concentrations were quantified by high performance liquid chromatography (HPLC). Vascular leakiness (K (PS)) was calculated based on the MRI data using a pharmacokinetic model., Results: K (PS) was calculated as 3.70 +/- 1.12 (control tumors), 1.95 +/- 0.70 (0.1 mg group) and 0.75 +/- 0.46 microl min (-1)cm (-3) (1.0 mg group). K (PS) was significantly higher in the control group compared to the 1.0 mg bevacizumab group. Vinorelbine concentrations were measured as 409.4 +/- 109.7 (control tumors), 387.5 +/- 47.5 (0.1 mg group) and 250.7 +/- 71.9 (1.0 mg group). These differences were not significant. A moderate and significant correlation was found between K (PS) and Vinorelbine concentrations in tumors (r = 0.49, p < 0.05)., Conclusion: MRI-assayed K (PS) based on dynamic MRI enhanced by albumin-(Gd-DTPA) (30) correlated significantly with vinorelbine accumulation in experimental xenograft tumors under angiogenesis inhibition. Thus, the MRI technique applied in our study could potentially help to predict accumulation of macromolecular cytotoxic drugs and to optimize individual therapeutic regimes in tumors.
- Published
- 2010
- Full Text
- View/download PDF
15. [Atypical case of bronchus carcinoma].
- Author
-
Chatterjee B, Berger D, Joost Ch, and Stucki A
- Subjects
- Antidiuretic Agents therapeutic use, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms drug therapy, Brain Neoplasms radiotherapy, Carboplatin administration & dosage, Carboplatin therapeutic use, Deamino Arginine Vasopressin therapeutic use, Diabetes Insipidus complications, Diabetes Insipidus diagnosis, Diabetes Insipidus drug therapy, Diagnosis, Differential, Humans, Lung pathology, Male, Middle Aged, Neoplasm Metastasis, Palliative Care, Polyuria complications, Radiography, Thoracic, Radiotherapy Dosage, Vinblastine administration & dosage, Vinblastine analogs & derivatives, Vinblastine therapeutic use, Vinorelbine, Brain Neoplasms secondary, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms diagnostic imaging, Lung Neoplasms mortality, Lung Neoplasms pathology
- Abstract
Bronchuscarcinoma ist the most frequent death cause with tumor patients. At time of diagnosis the stadium is often already advanced, the patient is inoperable. We present a patient (non-smoker) with polydipsia, visual troubles and polyuria. The lab results confirmed diabetes insipidus, but the following x-rays proved multiple intracerebral spots. And also multiple spots in the lungs, the mediastinum, in the liver, the coloumn and the adrenals. Histological diagnosis was non small cell lung cancer (NSCLC).
- Published
- 2008
- Full Text
- View/download PDF
16. [Palliative chemotherapy of head and neck cancer: present status and future development].
- Author
-
Hennemann B
- Subjects
- Animals, Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic therapeutic use, Antineoplastic Agents administration & dosage, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic therapeutic use, Cisplatin administration & dosage, Clinical Trials as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Disease Progression, ErbB Receptors antagonists & inhibitors, Forecasting, Gefitinib, Head and Neck Neoplasms mortality, Humans, Neoplasm Metastasis, Neoplasm Recurrence, Local drug therapy, Palliative Care, Patient Selection, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors therapeutic use, Quinazolines administration & dosage, Quinazolines therapeutic use, Rats, Taxoids administration & dosage, Taxoids adverse effects, Time Factors, Treatment Outcome, Vinblastine administration & dosage, Vinblastine analogs & derivatives, Vinblastine therapeutic use, Vinorelbine, Gemcitabine, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cisplatin therapeutic use, Head and Neck Neoplasms drug therapy, Protein-Tyrosine Kinases antagonists & inhibitors, Taxoids therapeutic use
- Abstract
Background: Patients with head and neck tumors are treated with palliative chemotherapy in case of the detection of distant metastases or local recurrence without the option of surgical therapy or radiation. Alongside 5-fluorouracil (5-FU) in combination with cisplatin or carboplatin, taxanes, gemcitabine and vinorelbine as well as monoclonal antibodies or small molecule tyrosine kinase inhibitors have been used., Methods: This review analyses the published literature of the past 15 years, including selected abstracts with view to response rate, overall survival and adverse effects., Results: 5-FU plus cisplatin or carboplatin can still be considered as standard treatment, achieving response rates of 20-30 %. The addition of taxanes increases the objective response rate but adds remarkable toxicity to the treatment protocol. Phase III studies demonstrate higher response rates but fail to demonstrate a significant increase of the overall survival after polychemotherapy as compared to monotherapy protocols. Thus, patients with a reduced performance can be treated with monotherapy. In case of disease progression after cisplatin-containing chemotherapy further treatment should only be offered to selected patients. For this situation, platin-free chemotherapy protocols containing taxanes, gemcitabine or vinorelbine seem promising. Recent studies with monoclonal antibodies or small molecule tyrosine kinase inhibitors report on a response rate of 10-20 %., Conclusion: The use of new drugs increases the response rate and amends the side effects of the chemotherapy. However, phase III studies documenting an improved overall survival are lacking. Targeted therapies broaden the therapeutic armament, and possibly, EGFR inhibition will help to overcome chemotherapy resistance in the future.
- Published
- 2006
- Full Text
- View/download PDF
17. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
- Author
-
Bartsch V
- Subjects
- Administration, Oral, Antineoplastic Agents, Phytogenic adverse effects, Antineoplastic Agents, Phytogenic pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biological Availability, Breast Neoplasms blood, Breast Neoplasms mortality, Breast Neoplasms pathology, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Chemotherapy, Adjuvant, Clinical Trials as Topic, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Lung Neoplasms blood, Lung Neoplasms mortality, Lung Neoplasms pathology, Neoplasm Staging, Survival Rate, Treatment Outcome, Vinblastine administration & dosage, Vinblastine adverse effects, Vinblastine pharmacokinetics, Vinorelbine, Antineoplastic Agents, Phytogenic administration & dosage, Breast Neoplasms drug therapy, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Vinblastine analogs & derivatives
- Abstract
The development of an oral formulation of vinorelbine (Navelbine softgelatine capsules, Pierre Fabre Pharma, Freiburg i.Br., Germany) represents a significant advance in the treatment of patients with cancer. Oral chemotherapy is more convenient for the patients and brings significant time savings. Vinorelbine is rapidly absorbed after oral ingestion. The bioavailability is in the range of 33 to 43% and is not affected by concomitant food intake or by vomiting occuring 1.5 h or later after dosing. No significant differences in the pharmacokinetics of oral vinorelbine were observed between elderly (> or =70 years) and younger patients. The recommended dose schedule for oral vinorelbine is 60 mg/m(2) weekly for the initial 3 weeks (cycle 1) and 80 mg/m(2) weekly thereafter. However, if severe neutropenia is encountered during the first cycle, treatment is continued with weekly doses of 60 mg/m(2). Bioavailability studies have demonstrated that oral vinorelbine doses of 60 and 80 mg/m(2) are comparable to intravenous doses of 25 and 30 mg/m(2), respectively. Several clinical studies have demonstrated that the new oral formulation of vinorelbine can be safely administered, even to elderly patients, and is comparable in activity to intravenous vinorelbine in advanced non-small cell lung cancer (NSCLC) and metastatic breast cancer (MBC). A randomized phase II comparison of oral vinorelbine at the recommended dose schedule vs. intravenous vinorelbine at 30 mg/(2) in patients with advanced NSCLC found no significant differences in response rate, progression-free and overall survival between the two treatments. In studies of combination chemotherapy using vinorelbine plus cisplatin or carboplatin in advanced NSCLC, or vinorelbine plus taxanes, capecitabine,epirubicin, or the monoclonal HER2/neu antibody trastuzumab in MBC, intravenous vinorelbine could be completely or partially replaced by oral vinorelbine, resulting in maintained efficacy, good tolerability and improved patient convenience. Concurrent chemoradiation with oral vinorelbine and cisplatin was shown to be well tolerated and produced significant down-staging in patients with locally advanced NSCLC. Metronomic chemotherapy is a new treatment approach designed to maximize the antiangiogenic effect. Oral vinorelbine given every other day at low doses is currently evaluated in patients with refractory solid tumors. Oral vinorelbine has also proven useful as a substitute for intravenous vinorelbine in patients experiencing intractable acute tumor pain during or after intravenous infusion of vinorelbine.
- Published
- 2006
- Full Text
- View/download PDF
18. [Combination therapy herceptin+taxotere/Herceptin+navelbine].
- Author
-
Meden H
- Subjects
- Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast drug effects, Breast pathology, Breast Neoplasms pathology, Docetaxel, Female, Humans, In Situ Hybridization, Fluorescence, Neoplasm Staging, Pilot Projects, Taxoids adverse effects, Trastuzumab, Vinblastine administration & dosage, Vinblastine adverse effects, Vinorelbine, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Receptor, ErbB-2 genetics, Taxoids administration & dosage, Vinblastine analogs & derivatives
- Published
- 2002
19. [Vinorelbine in patients with malignant pleural mesothelioma--a phase II study].
- Author
-
Ost E and Illiger HJ
- Subjects
- Drug Administration Schedule, Follow-Up Studies, Humans, Mesothelioma pathology, Neoplasm Staging, Pleural Neoplasms pathology, Quality of Life, Treatment Outcome, Vinblastine adverse effects, Vinblastine analogs & derivatives, Vinorelbine, Mesothelioma drug therapy, Pleural Neoplasms drug therapy, Vinblastine therapeutic use
- Published
- 2001
20. [Adverse (cardio-)vascular effects of vinorelbine in non-small-cell bronchial carcinoma].
- Author
-
Kirschner J, Kolb M, Müller J, and Jacobi I
- Subjects
- Aged, Angina Pectoris diagnosis, Antineoplastic Agents, Phytogenic administration & dosage, Carcinoma, Non-Small-Cell Lung pathology, Electrocardiography drug effects, Humans, Hypertension diagnosis, Lung Neoplasms pathology, Male, Middle Aged, Myocardial Infarction diagnosis, Risk Factors, Vinblastine administration & dosage, Vinblastine adverse effects, Vinorelbine, Angina Pectoris chemically induced, Antineoplastic Agents, Phytogenic adverse effects, Carcinoma, Non-Small-Cell Lung drug therapy, Hypertension chemically induced, Lung Neoplasms drug therapy, Myocardial Infarction chemically induced, Vinblastine analogs & derivatives
- Abstract
Vinorelbin is an important tumouricidal substance. The (cardio-)vascular side effects are not well known. We report on four patients in highly palliative situations who were treated with vinorelbine for non-small cell lung cancer. Case one presented with myocardial infarction eleven days after onset of therapy. The second and third cases had to be admitted immediately after the beginning of vinorelbine treatment because of hypertension and angina pectoris. The fourth case suffered from angina abdominalis. A critical review of the literature showed 17 cardiac ischaemias with seven myocardial infarctions, three of them with lethal outcome.
- Published
- 2000
- Full Text
- View/download PDF
21. [New cytostatics in the therapy of non-small cell bronchial carcinoma].
- Author
-
Serke M, Schönfeld N, and Loddenkemper R
- Subjects
- Deoxycytidine therapeutic use, Humans, Vinblastine therapeutic use, Vinorelbine, Gemcitabine, Antimetabolites, Antineoplastic therapeutic use, Antineoplastic Agents, Phytogenic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bridged-Ring Compounds therapeutic use, Bronchial Neoplasms drug therapy, Carcinoma, Non-Small-Cell Lung drug therapy, Deoxycytidine analogs & derivatives, Lung Neoplasms, Paclitaxel therapeutic use, Taxoids, Vinblastine analogs & derivatives
- Published
- 1998
22. [Phlebitis after vinorelbine].
- Author
-
Sauter C, Margulies A, and Pestalozzi B
- Subjects
- Antineoplastic Agents, Phytogenic administration & dosage, Humans, Infusions, Intravenous, Vinblastine administration & dosage, Vinblastine adverse effects, Vinorelbine, Antineoplastic Agents, Phytogenic adverse effects, Neoplasms drug therapy, Phlebitis chemically induced, Vinblastine analogs & derivatives
- Published
- 1998
23. [Navelbine (Vinorelbin)--current trends and results. Satellite symposium of the 22nd German Cancer Congress. Berlin, 20 February 1996].
- Subjects
- Antineoplastic Agents, Phytogenic administration & dosage, Breast Neoplasms drug therapy, Female, Humans, Vinblastine administration & dosage, Vinblastine therapeutic use, Vinorelbine, Antineoplastic Agents, Phytogenic therapeutic use, Vinblastine analogs & derivatives
- Published
- 1996
24. [Navelbine (Vinorelbin)--current trends and results. Satellite-Symposium on occasion of the 22nd German Cancer Congress. Berlin, 20 February 1996].
- Subjects
- Antineoplastic Combined Chemotherapy Protocols, Berlin, Female, Humans, Vinblastine therapeutic use, Vinorelbine, Antineoplastic Agents, Phytogenic therapeutic use, Breast Neoplasms drug therapy, Bronchial Neoplasms drug therapy, Vinblastine analogs & derivatives
- Published
- 1996
25. [Navelbine (Vinorelbin)--current trends and results. Satellite Symposium on occasion of the 22nd German Cancer Congress. Berlin, 20 February 1996].
- Subjects
- Antineoplastic Agents, Phytogenic therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Female, Humans, Lung Neoplasms drug therapy, Vinblastine therapeutic use, Vinorelbine, Breast Neoplasms drug therapy, Bronchial Neoplasms drug therapy, Vinblastine analogs & derivatives
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.